It was the best of times, it was the worst of times... --Charles Dickens.
These words sum up the state of Alzheimer’s disease (AD) research, specifically therapy development, over the last few years.
On the one hand, the budget climate and dismal therapeutic results cloud the future. On the other hand, there are tremendous opportunities presented by the U.S. National Plan to Address Alzheimer’s Disease and by the emergence of systems and precision medicine. These could transform AD research and drug development.